The strong safety and durability signals from the OLE reduce binary risk ahead of the NOV-ERA Phase 2b readout. Watch for enrollment initiation and any KOL commentary from today's webcast; the 400 mg BID arm inclusion is a positive dose-ranging signal.
Price Chart
Executive Summary
Agomab reported positive topline data from the 48-week open-label extension (OLE) of the Phase 2a STENOVA trial for ontunisertib in fibrostenosing Crohn's disease (FSCD). Key results include a favorable long-term safety profile, a low annualized FSCD-related event rate of 3% (one EBD, no surgeries), and sustained disease control, supporting the planned initiation of the global NOV-ERA Phase 2b study. This is a material clinical catalyst for a pre-revenue biotech, de-risking the program's safety and durability profile.
Key Facts
- 94% of eligible patients (n=49) rolled over into the OLE from Part A; 37 completed 48 weeks.
- Annualized FSCD-related event rate of 3% (one EBD, no surgeries) over up to 60 weeks of ontunisertib 200 mg BID.
- No signals of cardiac injury, pro-inflammatory effects, vasculitis, liver toxicity, or thrombotic events.
- 97% of evaluable patients were in clinical remission at Week 48 per CDAI score.
- MRE imaging suggested radiological stabilization of fibrotic strictures over the treatment course.
- Regulatory filings for the global NOV-ERA Phase 2b trial (~320 patients, 3 dose levels vs placebo) recently completed; initiation expected in coming months.
- Ontunisertib has U.S. FDA Fast Track Designation.
Financial Impact
Positive clinical data de-risks a lead pipeline asset for a pre-revenue biotech; no revenue or earnings figures reported.
Risk Factors
- OLE data is open-label and uncontrolled; efficacy signals are exploratory and may not replicate in the randomized Phase 2b.
- Cross-trial event rate comparisons (23-35% for advanced therapies) are not head-to-head and may be misleading.
- NOV-ERA Phase 2b enrollment and execution risk remain; no approved therapy for FSCD exists, creating regulatory uncertainty.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-112564 |
| Document: tm2626748d1_6k.htm | 0001104659-26-112564 |
| Document: 0001104659-26-112564-index-headers.html | 0001104659-26-112564 |
| Document: 0001104659-26-112564-index.html | 0001104659-26-112564 |
| Document: 0001104659-26-112564.txt | 0001104659-26-112564 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Insider Buy | $9.26 | awaiting T+5 | — | $9.05 (−2.27%) |
Oct 13, 2026 13d ago | 6-K | $8.69 $9.11 | ▲ +4.83% | ▲ +4.38% | $9.05 (+4.14%) |
Oct 13, 2026 13d ago | Press Release | $8.69 $9.11 | ▲ +4.83% | ▲ +4.38% | $9.05 (+4.14%) |
Oct 1, 2026 25d ago | 6-K | $8.65 $9.22 | ▲ +6.59% | ▲ +5.29% | $9.05 (+4.62%) |
Oct 1, 2026 25d ago | Press Release | $8.65 $9.22 | ▲ +6.59% | ▲ +5.29% | $9.05 (+4.62%) |
Sep 14, 2026 6w ago | 6-K | $12.16 $11.49 | ▼ −5.51% | ▼ −7.64% | $9.05 (−25.58%) |
Sep 14, 2026 6w ago | Press Release | $12.16 $11.49 | ▼ −5.51% | ▼ −7.64% | $9.05 (−25.58%) |
Sep 11, 2026 6w ago | 6-K | $12.28 $11.70 | ▼ −4.72% | ▼ −4.83% | $9.05 (−26.30%) |
Aug 10, 2026 11w ago | 6-K | $14.85 $13.73 | ▼ −7.54% | ▼ −7.14% | $9.05 (−39.06%) |
Jun 23, 2026 17w ago | 6-K | $12.68 $11.87 | ▼ −6.39% | ▼ −8.10% | $9.05 (−28.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers